ZVSA Form 25: Nasdaq Delisting Notice Filed

Rhea-AI Filing Summary

ZyVersa Therapeutics, Inc. (ZVSA) submitted a Form 25 notice indicating removal of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies the issuer's principal office in Weston, Florida, and provides a contact telephone number. The form lists the regulatory provisions for voluntary or exchange-initiated delisting under 17 CFR 240.12d2-2 and certifies Nasdaq's compliance with the rule for striking the class from listing and/or registration.

Positive

• None.

Negative

• Filing notifies removal of securities from Nasdaq listing/registration
• Form lacks an explicit effective date or explanation for the removal

Insights

Exchange Listing Specialist

Form 25 notifies removal from Nasdaq; this is a material market event.

The filing documents that the issuer's securities will be struck from listing and/or registration on the Nasdaq Stock Market LLC under the cited 17 CFR 240.12d2-2 provisions. Removal may follow either an exchange determination or a voluntary withdrawal route, both referenced in the notice.

Delisting affects trading venue and regulatory status immediately after processing; investors and counterparties typically update trading arrangements within days to weeks. Monitor formal delisting effective date and any subsequent transfer to an alternative trading market.

Corporate Governance Analyst

The notice certifies Nasdaq compliance but provides no reasoning or effective date.

The form certifies that Nasdaq has ‘‘reasonable grounds’’ to file Form 25 and references exchange compliance with rule procedures. It does not disclose the cause (e.g., failure to meet listing standards) nor an explicit removal/effective date.

Key near-term items to watch are any follow-up filings that state the delisting effective date, shareholder notices, or filings that explain whether the removal is voluntary or exchange-initiated.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-41184

Issuer:	ZyVersa Therapeutics, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	2200 N. Commerce Parkway, Suite 208
	Weston	FLORIDA	33326
Telephone number:					(754) 231-1688

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-10-06	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 25 for ZyVersa Therapeutics (ZVSA) mean?

The Form 25 notifies that ZyVersa's securities will be removed from listing and/or registration on the Nasdaq Stock Market LLC under 17 CFR 240.12d2-2.

Does the filing say why ZVSA is being removed from Nasdaq?

No. The filing certifies the removal under the cited exchange rules but does not state the reason for the delisting.

Is there an effective date for the Nasdaq removal in the filing?

No. The document does not disclose an effective date for the removal.

Where is ZyVersa Therapeutics headquartered according to the filing?

The filing lists the issuer's principal executive offices at 2200 N. Commerce Parkway, Suite 208, Weston, Florida 33326 and telephone (754) 231-1688.

What regulatory provision is cited for the delisting?

The filing cites 17 CFR 240.12d2-2 and related procedural provisions governing removal from listing and/or registration.